3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
4
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma
2
Recurrence
1
Ototoxicity
1
Neoplasm, Residual
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Hematologic Neoplasms
1
Central Nervous System Neoplasms
1
Interventions
Blood Specimen Collection
6
Liquid Biopsy
3
Chemotherapy, Adjuvant
2
trastuzumab deruxtecan
1
pegaspargase
1
Vincristine
1
Trastuzumab
1
Transplantation, Autologous
1
Prednisone
1
Neoadjuvant Therapy
1
Methotrexate
1
Mercaptopurine
1
Hematologic Tests
1
Drug Therapy
1
Doxorubicin
1
Daunorubicin
1
Cytoreduction Surgical Procedures
1
Cytarabine
1
Cyclophosphamide
1
Clonal Evolution
1
Anti-Inflammatory Agents, Non-Steroidal
1
Aminolevulinic Acid
1
Ado-Trastuzumab Emtansine
1
Adjuvants, Pharmaceutic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Neoplasm, Residual
×
Vincristine
×
Clear all
NCT05959720
2025-05-07
BRALLA
Instituto do Cancer do Estado de São Paulo
Recruiting
180 enrolled